



PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/730,776
		Filing Date	December 8, 2003
		First Named Inventor	Michael LIEBERMAN
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	12 + 6: Refs	Attorney Docket Number	247332001100

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement, 3 pages <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form 1449, 4 pages in duplicate (6/1) References Return Postcard
<div>Remarks</div> <p>CUSTOMER NO. 25225</p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP James J. Mullen, III - 44,957
Signature	
Date	March 17, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 3-17-2004 Signature: Rhea Amid (Rhea Amid)



PATENT
Docket No. 247332001100

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on March 17, 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Michael LIEBERMAN

Serial No.: 10/730,776

Filing Date: December 8, 2003

For: RECOMBINANT VACCINE AGAINST
FLAVIVIRUS INFECTION

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are not submitted. Copies of non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does


not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 247332001100. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 17, 2004


Respectfully submitted,

By:



James J. Mullen, III, Ph.D.
Registration No. 44,957

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7940
Facsimile: (858) 720-5125



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Docket Number 247332001100

Application Number 10/730,776

Applicant

Michael LIEBERMAN

Filing Date December 8, 2003

Group Art Unit To Be Assigned

Mailing Date March 17 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.		09/376,463				August 18, 1999
	2.	10/1991	5,057,540	Kensil et al.	514	25	
	3.	12/1996	5,583,112	Kensil et al.	514	25	
	4.	09/1997	5,663,153	Hutcherson et al.	514	44	
	5.	10/1997	5,679,354	Morein et al.	424	278.1	
	6.	03/1998	5,723,335	Hutcherson et al.	435	375	
	7.	10/2000	6,136,561	Ivy et al.	435	69.3	
	8.	12/2000	6,165,477	Ivy et al.	424	218.1	
	9.	02/2001	6,194,388	Krieg et al.	514	44	
	10.	03/2001	6,207,646	Krieg et al.	514	44	
	11.	04/2001	6,214,806	Krieg et al.	514	44	
	12.	04/2001	6,218,371	Krieg et al.	514	44	
	13.	05/2001	6,231,859	Kensil	424	184.1	
	14.	05/2001	6,239,116	Krieg et al.	514	44	
	15.	07/2001	6,262,029	Press et al.	514	26	
	16.	01/2002	6,339,068	Krieg et al.	514	44	
	17.	06/2002	6,406,705	Davis et al.	424	278.1	
	18.	07/2002	6,416,763	McDonell et al.	424	218.1	
	19.	08/2002	6,429,199	Krieg et al.	514	44	
	20.	08/2002	6,432,411	Ivy et al.	424	218.1	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Docket Number 247332001100	Application Number 10/730,776
	Applicant Michael LIEBERMAN	
	Filing Date December 8, 2003	Group Art Unit To Be Assigned
	Mailing Date March 17, 2004	

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	21.	Angsubhakorn et al., Southeast Asian J. Trop. Med. Public Health (1994) 25:554-559
	22.	Ballas et al., J. of Immunology (2001) 167:4878-4886
	23.	Bhamarapravati et al., Bull. World Health Organ. (1987) 65:189-195
	24.	Bhamarapravati and Sutee, Vaccine (2000) Suppl 2:44-47
	25.	Bray and Lai, Proc. Natl. Acad. Sci. USA (1991) 88:10342-10346
	26.	Bray et al., J. Virol. (1996) 70:4162-4166
	27.	Cane et al., J. Gen. Virol., (1988) 69:1241-1246
	28.	Cardosa, Brit. Med. Bull. (1998) 54:395-405
	29.	Chambers et al., Annual Rev Microbiol (1990) 44:649-688
	30.	Chen et al., J. Virol. (1995) 69:5186-5190
	31.	Chu et al., J. Exp. Med. (1997) 186:1623
	32.	Cox and Coulter, Vaccine (1997) 15:248-256
	33.	Culp et al., Biotechnology (NY) (1991) 9:173-177
	34.	Dharakul et al., J. Infect. Dis. (1994) 170:27-33
	35.	Edelman et al., J. Infect. Dis. (1994) 170:1448-1455
	36.	Elias et al., J. Immun. (2003) 171:3697-3704
	37.	Falgout et al., J. Virol., (1990) 64(9):4356-4363
	38.	Fleeton et al., J. Gen. Virol (1999) 80:1189-1198
	39.	Gupta and Siber, Vaccine (1995) 13:1263-1276
	40.	Hall et al., J. Gen. Virol., (1996) 77:1287-1294
	41.	Hartmann and Krieg, J. Immunol. (2000) 164:944-952
	42.	Hartmann et al., J. of Immunol. (2000) 164:1617-1624
	43.	Heinz et al., Virology (1983) 130:485-501
	44.	Henchal et al., Am. J. Trop. Med. Hyg. (1985) 34:162-169
	45.	Henchal and Putnak, Clin Microbiol Rev. (1990) 3:376-396
	46.	Hoke et al., Am. J. Trop. Med. Hyg. (1990) 43:219-226

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Docket Number 247332001100	Application Number 10/730,776
		Applicant Michael LIEBERMAN	
		Filing Date December 8, 2003	Group Art Unit To Be Assigned
		Mailing Date March <u>17</u> , 2004	
	47.	Ivey-Hoyle, Curr. Opin. Biotechnol. (1991) 2:704-707	
	48.	Jan et al., Am. J. Trop. Med. Hyg., 48(3), (1993) pp. 412-423	
	49.	Jacobs et al., J. of Gen. Virol. (1994) 75:2399-2402	
	50.	Johansen et al., Genes Dev. (1989) 3:882-889	
	51.	Kanesa-athan et al., Vaccine (2001) 19:3179-3188	
	52.	Katial et al., J. Clin. Immunol. (1997) 17:34-42	
	53.	Katial et al., Clin. Diagn. Lab. Immunol. (1998) 5:78-81	
	54.	Kensil et al., J. Immunol. (1991) 146:431-437	
	55.	Kimura-Kiroda and Yasui, J. Immunol. (1988) 141:3606-3610	
	56.	Krieg et al., Nature (1995) 374:546	
	57.	Lai et al., Clin. Diagn. Virol. (1998) 10:173-179	
	58.	Livingston et al., J. Immunol. (1995) 154:1287-1295	
	59.	Mackenzie et al., Virol., (1996) 220:232-240	
	60.	Mason, J. Gen Virol (1989) 70:2037-2048	
	61.	Mathew et al., J. Clin. Invest. (1996) 98:1684-1692	
	62.	Men et al., J. Virol (1991) 65:1400-1407	
	63.	Moingeon, Biotechnol (2002) 98:189-198	
	64.	Newman et al., J. Immunol. (1992) 148:2357-2362	
	65.	Oxenius et al., J. Virol. (1999) 73: 4120	
	66.	Rey et al., Nature (1995) 375:291-298	
	67.	Russell and Nisalak, J. Immunol. (1967) 99:285-290	
	68.	Sabchareon et al., Am. J. Trop. Med. Hyg. (2002) 66:264-272	
	69.	Schlesinger et al., J. Immunol., (1985) 135(4):2805-2809	
	70.	Schlesinger et al., J. Virol., (1986) 60(3):1153-1155	
	71.	Schlesinger, et al., J. Gen. Virol. (1987) 68:853-857	
	72.	Schlesinger et al., J. Gen. Virol. (1990) 71:593-599	
	73.	Schlesinger et al., Virology (1993) 192:132-14	
	74.	Tesh et al., Emerg. Infect. Dis. 8:1392-1397 (2002)	
	75.	Trirawatanapong et al., Gene (1992) 116:139-150	
	76.	Vaughn et al., Vaccine (1996) 14:329-336	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Docket Number 247332001100	Application Number 10/730,776
		Applicant <div style="text-align: center;">Michael LIEBERMAN</div>	
		Filing Date December 8, 2003	Group Art Unit To Be Assigned
		Mailing Date March <u>17</u> , 2004	
	77.	Verthelyi & Klinman, Clinical Immunology, 109:64-71 (2003)	
	78.	Wang et al, Vaccine (2003) 21:4297-4306	
	79.	Weeratna et al., Vaccine (2000) 18:1755-1762	
	80.	Xiao et al., Emerg. Infect. Dis. 7:714-721 (2001)	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			